January 23, 2006 10:07 ET

Nymox NX-1207 Pivotal Trial Gets Positive Efficacy and Safety Recommendation from Independent Data Monitoring Committee

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Jan 23, 2006) -

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report that the Independent Data Monitoring Committee for the Company's pivotal trial of NX-1207 for benign prostatic hyperplasia (BPH) has given a positive recommendation based on evaluation of the data in the Company's current pivotal Phase 2 trial. The Independent Data Monitoring Committee is an arm's length independent body which has examined unblinded trial results and reached a favorable conclusion, and has recommended continuation of the trial.

Paul Averback MD, CEO of Nymox, said, "We are excited by the overall near-term prospects of NX-1207, and look forward to the trial's completion. There is considerable and growing interest in Nymox's new BPH drug."

NX-1207 has completed two earlier Phase 1 and 2 trials where the drug produced on average over 23% prostate shrinkage in 1 month with minimal side effects. Overall there have been no sexual side effects, and a better side effect profile compared to existing drugs. The symptomatic improvement in earlier trials reached 10 points on the BPH Symptom Score, which is far superior to available drugs, and compares to invasive and surgical treatments.

BPH afflicts approximately half of men over age 50 and close to 90% of men by age 80. The disorder causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX